Photo from wikipedia
Abstract Longer term efficacy results in Japanese patients enrolled in PREVAIL demonstrate continued treatment benefit of enzalutamide compared with placebo in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate… Click to show full abstract
Abstract Longer term efficacy results in Japanese patients enrolled in PREVAIL demonstrate continued treatment benefit of enzalutamide compared with placebo in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
Keywords:
prostate cancer;
japanese patients;
enzalutamide;
metastatic castration;
castration resistant;
resistant prostate
Journal Title: Japanese Journal of Clinical Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Japanese Journal of Clinical Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!